Search results for "Epitopes"

showing 10 items of 254 documents

Analysis of antigens recognized on human melanoma cells by A2-restricted cytolytic t lymphocytes (CTL)

1993

We have pursued our analysis of potential tumor-rejection antigens recognized on human melanoma by autologous cytolytic T lymphocytes (CTL). We reported previously that 3 distinct antigens (A,B,C) were recognized on melanoma cell line SK29-MEL in association with HLA-A2. Selection for melanoma-cell variants resistant to anti-A CTL revealed that antigen A consists of at least 2 determinants (Aa, Ab) which can be lost separately. Genetic linkage between Aa and Ab was suggested by concomitant loss of Aa and Ab in an immunoselected tumor-cell variant. This variant was also resistant to an autologous CTL clone restricted by HLA-B45, indicating that this CTL may also recognize a determinant of an…

Cancer ResearchClone (cell biology)T lymphocyteBiologyCytotoxicity Tests ImmunologicTransfectionVirologyEpitopesCytolysisCTL*OncologyLytic cycleAntigenAntigens NeoplasmHLA-B AntigensHLA-A2 AntigenGene expressionImmunologyTumor Cells CulturedHumansCloning MolecularCytotoxicityMelanomaT-Lymphocytes CytotoxicInternational Journal of Cancer
researchProduct

Overlapping peptides of melanocyte differentiation antigen melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B4…

1998

From the peripheral blood lymphocytes (PBLs) of melanoma patient SK29(AV) we have previously isolated 2 independent cytolytic T lymphocyte (CTL) clones (CTL7/147 and CTL13/211), which lysed autologous tumor cells in association with HLA-B45.1. As demonstrated here, both CTL clones were directed against melanocyte differentiation antigen Melan-A/MART-1, which also was recognized by HLA-A2.1-restricted CTLs from the same patient. By generating and transfecting 3'-deletion mutants of Melan-A/MART-1 cDNA, we localized its peptide-coding regions. The HLA-B45.1-presented peptides were derived from a hydrophobic region of the protein and largely overlapped the peptides recognized by CTLs from the …

Cancer ResearchEpitopes T-LymphocytePeptideHuman leukocyte antigenBiologyEpitopeMART-1 AntigenMelanocyte differentiationAntigenAntigens NeoplasmHLA-A2 AntigenTumor Cells CulturedAnimalsHumansAmino Acid SequenceMelanomachemistry.chemical_classificationBase SequenceSequence Homology Amino AcidDNA NeoplasmT lymphocyteVirologyNeoplasm ProteinsCTL*OncologychemistryHLA-B AntigensCOS CellsClone (B-cell biology)T-Lymphocytes CytotoxicInternational Journal of Cancer
researchProduct

The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation.

2010

Abstract Colon cancer stem cells (CSC) can be identified with AC133, an antibody that detects an epitope on CD133. However, recent evidence suggests that expression of CD133 is not restricted to CSCs, but is also expressed on differentiated tumor cells. Intriguingly, we observed that detection of the AC133 epitope on the cell surface decreased upon differentiation of CSC in a manner that correlated with loss of clonogenicity. However, this event did not coincide with a change in CD133 promoter activity, mRNA, splice variant, protein expression, or even cell surface expression of CD133. In contrast, we noted that with CSC differentiation, a change occured in CD133 glycosylation. Thus, AC133 …

Cancer ResearchGlycosylationGlycosylationCellular differentiationCellAC 133 EpitopeDown-RegulationMice SCIDEpitopechemistry.chemical_compoundEpitopesMiceCancer stem cellAntigens CDMice Inbred NODProminin-1medicineTumor Cells CulturedAnimalsHumansProtein IsoformsAC133 AntigenRNA MessengerPromoter Regions GeneticneoplasmsGlycoproteinsbiologyCell DifferentiationMolecular biologycarbohydrates (lipids)Gene Expression Regulation Neoplasticmedicine.anatomical_structureOncologychemistryembryonic structuresColonic Neoplasmsbiology.proteinNeoplastic Stem CellsAntibodyStem cellPeptidesCancer research
researchProduct

Immunorecognition of different ganglioside epitopes on human normal and melanoma tissues.

1992

There is increasing evidence that cell-surface gangliosides play a role in tumor growth, progression and metastases. In order to determine the frequency of ganglioside GD3 in patients with metastatic malignant melanoma for further therapeutic trials, GD3 ganglioside expression was determined in 119 tissue samples. Of these melanomas, 93% (111/119) were R-24-positive, which indicates the value of this diagnostic marker for melanoma. To study the structural epitopes of gangliosides, 10 ganglioside antibodies with defined specificities and affinities were tested on over 100 fresh-frozen tissue specimens of human normal and melanoma tissues. All the antibodies tested recognize the ganglioside G…

Cancer ResearchPathologymedicine.medical_specialtySkin Neoplasmsmedicine.drug_classmedicine.medical_treatmentMonoclonal antibodyEpitopeEpitopesGangliosidesmedicineGanglioside GD3HumansNeoplasm MetastasisMelanomaGangliosidebiologyMelanomaAntibodies MonoclonalImmunotherapymedicine.diseaseMolecular biologyImmunohistochemistryOncologybiology.proteinImmunohistochemistrylipids (amino acids peptides and proteins)AntibodyInternational journal of cancer
researchProduct

Functional TCR Retrieval from Single Antigen-Specific Human T Cells Reveals Multiple Novel Epitopes

2014

Abstract The determination of the epitope specificity of disease-associated T-cell responses is relevant for the development of biomarkers and targeted immunotherapies against cancer, autoimmune, and infectious diseases. The lack of known T-cell epitopes and corresponding T-cell receptors (TCR) for novel antigens hinders the efficient development and monitoring of new therapies. We developed an integrated approach for the systematic retrieval and functional characterization of TCRs from single antigen-reactive T cells that includes the identification of epitope specificity. This is accomplished through the rapid cloning of full-length TCR-α and TCR-β chains directly from single antigen-spec…

Cancer ResearchReceptors Antigen T-Cell/geneticsmedicine.medical_treatmentImmunologyReceptors Antigen T-CellEpitopes T-LymphocyteHistocompatibility Antigens Class I/immunologyComputational biologyBiologyEpitopeCell LineViral Matrix ProteinsMiceHistocompatibility Antigens Class II/immunologyAntigenAntigens NeoplasmT-Lymphocyte SubsetsmedicineAnimalsHumansViral Matrix Proteins/immunologyMembrane Proteins/geneticsCloning MolecularPhosphoproteins/immunologyAntigens Neoplasm/immunologyEpitopes T-Lymphocyte/immunologyHistocompatibility Antigens Class IT-cell receptorHistocompatibility Antigens Class IIPTEN PhosphohydrolasePTEN Phosphohydrolase/geneticsMembrane ProteinsRNAImmunotherapyPhosphoproteinsMolecular biologyT-Lymphocyte Subsets/immunologyIn vitroCell cultureCD8Protein BindingCancer Immunology Research
researchProduct

Naturally processed and HLA-B8-presented HPV16 E7 epitope recognized by T cells from patients with cervical cancer.

2004

Several major histocompatibility complex (MHC) alleles have been reported to present peptides derived from the HPV16 E7 oncoprotein to T cells. We describe an overrepresentation of the HLA-B8 allele (28.44%) in cervical cancer patients as compared to the MHC class I allele frequency in a local healthy control population (18.80%) and the identification of an HLA-B8-binding peptide TLHEYMLDL (HPV16 E77–15), which is able to drive HPV16 E7-specific and MHC class I-restricted T-cell responses in peripheral blood lymphocytes from healthy individuals. TLHEYMLDLspecific T cells recognize the naturally processed and presented peptide on HPV16 cervical cancer cells transfected with the HLA-B8 gene d…

Cancer ResearchReceptors CCR7Time FactorsCD8 AntigensPapillomavirus E7 ProteinsT-LymphocytesCD1Genes MHC Class IUterine Cervical NeoplasmsBiologyMajor histocompatibility complexEpitopeHLA-B8 AntigenEpitopesMHC class ICytotoxic T cellHumansLymphocytesAntigen-presenting cellAllelesAntigen Presentationvirus diseasesOncogene Proteins ViralNatural killer T cellFlow CytometryMolecular biologyOncologyMicroscopy FluorescenceLymphatic MetastasisImmunologybiology.proteinLeukocyte Common AntigensFemaleReceptors ChemokineLymph NodesPeptidesCD8International journal of cancer
researchProduct

Partial tyrosinase-specific self tolerance by HLA-A*0201-restricted cytotoxic T lymphocytes in mice and man

2003

The human tyrosinase (hTyr) (369-377) cytotoxic T lymphocyte (CTL) epitope is presented by malignant melanoma and various nontransformed cells in association with human leukocyte antigen (HLA)-A*0201 (A2.1) and used for vaccination-based immunotherapy of melanoma patients. Its mouse homologue, mTyr (369-377), is naturally processed and bound by A2.1 with equivalent efficacy and thus enabled us to explore the effect of self tolerance on Tyr-specific T cells in different lines of A2.1 transgenic (Tg) mice and man. We found that self Tyr-reactive CTL in Tg mice and, importantly, in man were affected by partial tolerance resulting in only residual T lymphocytes of higher avidity for self Tyr al…

Cancer ResearchT-LymphocytesGenetic VectorsMice Transgenicchemical and pharmacologic phenomenaBiologyEpitopeImmune toleranceEpitopesMiceImmune systemAntigenAntigens CDAntigens NeoplasmHLA-A2 AntigenAnimalsHumansCytotoxic T cellCTLA-4 AntigenIL-2 receptorMelanomaAntigen PresentationHLA-A AntigensMonophenol MonooxygenaseVaccinationReceptors Interleukin-2hemic and immune systemsAntigens DifferentiationMolecular biologyPeptide FragmentsMice Inbred C57BLCTL*Self ToleranceOncologySelf ToleranceImmunologyImmunotherapyT-Lymphocytes CytotoxicInternational Journal of Cancer
researchProduct

Long-term freedom from recurrence in 2 stage IV melanoma patients following vaccination with tyrosinase peptides.

2002

We report here on 2 patients who received adjuvant vaccination with an HLA-A2- or HLA-A24-restricted tyrosinase peptide, respectively, and GM-CSF for frequently relapsing stage IV melanoma. Following resection of metastases and irradiation of brain metastases in 1 patient, both patients were without evidence of disease when receiving the first vaccination. While the patients had had 9 and 12, respectively, mostly s.c., relapses during the 3 years before vaccination, they experienced freedom from relapse for more than 2 years after vaccination. We found a T-cell response to the vaccine peptide in both patients in the peripheral blood by ex vivo IFN-gamma ELISPOT assay. The T-cell population …

Cancer ResearchTime FactorsCD3 Complexmedicine.medical_treatmentCD8 AntigensT-LymphocytesPopulationTyrosinase PeptideCancer VaccinesPolymerase Chain ReactionDisease-Free SurvivalEpitopesInterferon-gammaRecurrencemedicineHumansRNA MessengerNeoplasm MetastasiseducationMelanomaeducation.field_of_studybiologybusiness.industryBrain NeoplasmsMonophenol MonooxygenaseMelanomaELISPOTImmunotherapymedicine.diseaseFlow CytometryImmunohistochemistryVaccinationOncologyGranzymeImmunologybiology.proteinbusinessPeptidesCD8International journal of cancer
researchProduct

Exome Sequencing to Predict Neoantigens in Melanoma

2015

Abstract The ability to use circulating peripheral blood cells and matched tumor sequencing data as a basis for neoantigen prediction has exciting possibilities for application in the personalized treatment of cancer patients. We have used a high-throughput screening approach, combining whole-exome sequence data, mRNA microarrays, and publicly available epitope prediction algorithm output to identify mutated proteins processed and displayed by patient tumors and recognized by circulating immune cells. Matched autologous melanoma cell lines and peripheral blood mononuclear cells were used to create mixed lymphocyte tumor cell cultures, resulting in an expansion of tumor-reactive T cells to u…

Cancer Researchbusiness.industryMelanomaLymphocyteImmunologyEpitopes T-LymphocyteDendritic cellCD8-Positive T-Lymphocytesmedicine.diseasePeripheral blood mononuclear cellEpitopeInterferon-gammaLymphocytes Tumor-Infiltratingmedicine.anatomical_structureImmune systemAntigenAntigens NeoplasmMutationImmunologyHumansMedicineExomebusinessMelanomaExome sequencingCancer Immunology Research
researchProduct

Onset of heart failure determines the hepatic cell death pattern.

2011

Background and rationale. Acute and chronic heart failure (HF) may affect the liver, but the underlying mechanisms that lead to progressive liver damage are poorly understood. The hepatic cytokeratin-18 (CK18) epitopes M65 and M30 have been reported to distinguish between overall (necrotic) and apoptotic cell death, respectively. We aimed to evaluate the predominant hepatic cell death pattern in acute vs. chronic heart failure and examined if these assays predict the course of the disease. Main results. In a prospective study comprising 21 patients with acute HF (AHF) and 18 patients with chronic HF (CHF) serum levels of M65 and M30 were assessed. Compared with CHF, M65 levels were signific…

Cell deathMalemedicine.medical_specialtyProgrammed cell deathMedizinM65Specialties of internal medicineApoptosisLiver injuryEpitopesPredictive Value of TestsInternal medicinemedicineHumansProspective StudiesProspective cohort studySurvival analysisHeart FailureLiver injuryKeratin-18HepatologyCytokeratin 18business.industryM30Liver DiseasesGeneral MedicineMiddle AgedPrognosismedicine.diseaseSurvival AnalysisRC581-951LiverApoptosisPredictive value of testsHeart failureAcute DiseaseChronic DiseaseHepatic stellate cellCardiologyFemalebusinessBiomarkers
researchProduct